Research Activity
Eikon pulls in $351M as lead drugs begins Phase III journey
Eikon Therapeutics Secures $350.7 Million Series D to Advance Cancer Drug Pipeline Eikon Therapeutics, a pivotal-stage biotechnology company, has raised $350.7 million in a Series D financing round to support its clinical-stage programs and future pipeline development147. This significant funding brings Eikon’s total capital raised since its founding in 2019 to over $1.1 billion17. ## […]
Legal Battle Erupts as Deerfield Accuses Alcon of Obstructing Aurion Biotech’s IPO Plans
Aurion Biotech, Alcon Research, Deerfield Management , Initial Public Offering (IPO), Legal dispute, Biotech industry, Corporate governance, Shareholder rights, Delaware Court of Chancery
Ex-CDER chief Patrizia Cavazzoni becomes Pfizers chief medical officer
Patrizia Cavazzoni, Pfizer ‘s, Pfizer, Cavazzoni
Pfizer taps former FDA drug chief Cavazzoni as new CMO
United States Food and Drug Administration, Pfizer, Cavazzoni, Center for Drug Evaluation and Research, Appointments, President brand of dental material
Entrada given go-ahead to test DMD therapy after two-year hold
Entrada, Muscular Dystrophy, Duchenne, DMD, United States Food and Drug Administration, Adult, Exons
Pfizer and Summit Therapeutics Collaborate on Innovative Cancer Therapy Combinations
Pfizer, Summit Therapeutics, ivonescimab, antibody-drug conjugates (ADCs), PD-1/VEGF bispecific antibody, solid tumors, clinical trials
Major Clinical Trial Failures of 2024: Setbacks in Neuroscience and Beyond
Clinical trials, drug development, neuroscience, ALS, Alzheimer’s disease, schizophrenia, Duchenne muscular dystrophy, oncology
Incyte and Genesis Therapeutics Forge $620M AI-Driven Drug Discovery Partnership
Artificial intelligence, drug discovery, small molecule therapeutics, GEMS platform, oncology, immunology, strategic collaboration
Illumina Announces Layoffs as Incyte Forges AI Partnership for Drug Discovery
Illumina, layoffs, Incyte, Genesis Therapeutics, AI partnership, drug discovery, GEMS platform, small molecule therapeutics
Supernus Pharmaceuticals’ Depression Drug SPN-820 Fails to Meet Primary Endpoint in Phase 2b Trial
Supernus Pharmaceuticals, SPN-820, treatment-resistant depression, Phase 2b trial, clinical study failure, MADRS score, placebo effect